Companies › Lubris Bio
2 active drug programs in 2 registered trials: 2 Phase 2; Ophthalmology, Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| rhPRG4 Recombinant human proteoglycan 4 (lubricin) | PRG4 | Phase 2 | Sjögren's Syndrome | Dec 2026 |
| rhPRG4 450 μg/ml Recombinant human proteoglycan 4 (lubricin analog) | PRG4 | Phase 2 | Ocular Graft Versus Host Disease | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07118241 | rhPRG4 | Phase 2 | Sjögren's Syndrome | Immunology | Dec 2026 |
| NCT07118254 | rhPRG4 450 μg/ml | Phase 2 | Ocular Graft Versus Host Disease | Ophthalmology | Mar 2027 |
–
MRM Health Triveni Bio Citryll Priovant Therapeutics Vantage Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.